We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Amgen's Multiple Myeloma Drug Receives NICE Recommendation
Read MoreHide Full Article
Amgen Inc. (AMGN - Free Report) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma (RMM) in patients who have received at least one prior therapy excluding Johnson & Johnson’s (JNJ - Free Report) Velcade.
The drug, in combination with Celgene Corporation’s Revlimid (lenalidomide) and dexamethasone, is already approved in the EU for the treatment of multiple myeloma in patients who have received at least one prior therapy. Moreover, the recommendation for label expansion from NICE, a public body of the Department of Health in the United Kingdom, will allow Amgen to market the drug with expanded label in England and Wales.
Amgen’s shares have outperformed the Zacks classified Medical - Biomedical and Genetics industry so far this year. The stock gained 12.8% compared with the industry’s increase of 2.3% during the period.
The recommendation was based on data from the pivotal ENDEAVOR study, which compared Kyprolis and Velcade in combination with dexamethasone in patients with RMM. The data demonstrated superiority of Kyprolis over Velcade by doubling progression-free survival (PFS) (18.7 months vs. 9.4 months) and significantly improving overall survival in patients.
Moreover, data from ASPIRE study showed that Kyprolis in combination with Revlimid and dexamethasone achieved better PFS than combination therapy with Revlimid and dexamethasone (26.3 months vs 17.6 months).
According to the company press release, there are approximately 17,500 patients with myeloma in the UK with news cases of approximately diagnosed every year.
Kyprolis posted sales of $190 million in the first quarter 2017, up 23% year over year, driven by higher demand. At the call, the company said that in the second-line multiple myeloma market, despite triplet regimens being used in approximately one-third of patients, Kyprolis gained 50% market share for new patient starts. With the approval of label expansion in the U.K., sales of this drug are likely to witness an increase.
Amgen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates declined from 50 cents to 39 cents for 2017 in the last 60 days. The company posted positive earnings surprises in the four trailing quarters with an average beat of 233.69%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
Image: Bigstock
Amgen's Multiple Myeloma Drug Receives NICE Recommendation
Amgen Inc. (AMGN - Free Report) announced that Kyprolis gained recommendation from National Institute for Health and Care Excellence (NICE) in combination with dexamethasone for the treatment of relapsed multiple myeloma (RMM) in patients who have received at least one prior therapy excluding Johnson & Johnson’s (JNJ - Free Report) Velcade.
The drug, in combination with Celgene Corporation’s Revlimid (lenalidomide) and dexamethasone, is already approved in the EU for the treatment of multiple myeloma in patients who have received at least one prior therapy. Moreover, the recommendation for label expansion from NICE, a public body of the Department of Health in the United Kingdom, will allow Amgen to market the drug with expanded label in England and Wales.
Amgen’s shares have outperformed the Zacks classified Medical - Biomedical and Genetics industry so far this year. The stock gained 12.8% compared with the industry’s increase of 2.3% during the period.
The recommendation was based on data from the pivotal ENDEAVOR study, which compared Kyprolis and Velcade in combination with dexamethasone in patients with RMM. The data demonstrated superiority of Kyprolis over Velcade by doubling progression-free survival (PFS) (18.7 months vs. 9.4 months) and significantly improving overall survival in patients.
Moreover, data from ASPIRE study showed that Kyprolis in combination with Revlimid and dexamethasone achieved better PFS than combination therapy with Revlimid and dexamethasone (26.3 months vs 17.6 months).
According to the company press release, there are approximately 17,500 patients with myeloma in the UK with news cases of approximately diagnosed every year.
Kyprolis posted sales of $190 million in the first quarter 2017, up 23% year over year, driven by higher demand. At the call, the company said that in the second-line multiple myeloma market, despite triplet regimens being used in approximately one-third of patients, Kyprolis gained 50% market share for new patient starts. With the approval of label expansion in the U.K., sales of this drug are likely to witness an increase.
Amgen Inc. Price
Amgen Inc. Price | Amgen Inc. Quote
Zacks Rank & Stock to Consider
Amgen currently carries a Zacks Rank #3 (Hold). A better-ranked stock in the healthcare sector is VIVUS, Inc. , sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
VIVUS’ loss per share estimates declined from 50 cents to 39 cents for 2017 in the last 60 days. The company posted positive earnings surprises in the four trailing quarters with an average beat of 233.69%.
Zacks' 2017 IPO Watch List
Before looking into the stocks mentioned above, you may want to get a head start on potential tech IPOs that are popping up on Zacks' radar. Imagine being in the first wave of investors to jump on a company with almost unlimited growth potential? This Special Report gives you the current scoop on 5 that may go public at any time.
One has driven from 0 to a $68 billion valuation in 8 years. Four others are a little less obvious but already show jaw-dropping growth. Download this IPO Watch List today for free >>